Predict your next investment

Corporation
HEALTHCARE | Biotechnology
cebix.com

See what CB Insights has to offer

Founded Year

2008

Stage

Dead | Dead

Total Raised

$59.89M

About Cebix

Cebix is developing Ersatta, a disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products simply directed at symptomatic relief, has the potential to reverse the chronic complications of diabetes.

Cebix Headquarter Location

12520 High Bluff Drive Suite 380

San Diego, California, 92130,

United States

858-729-6500

Latest Cebix News

Cebix hangs it up after raising $50M for diabetes drug

Feb 24, 2015

Reprint La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb. Last anyone heard from Cebix, it was powering into a mid-stage test of Ersatta, which is an analog of the body's natural C peptide hormone designed to combat loss of nerve function tied to Type 1 diabetes. The drug performed well in a Phase I/II bridge study, and, in 2012, Cebix embarked on a 250-patient Phase IIb efficacy trial to test how well Ersatta could improve nerve function compared to placebo, according to ClinicalTrials.gov . That study wrapped up in December, and Cebix concluded that "Ersatta and placebo were, alas, indistinguishable," CEO Joel Martin told Xconomy. Seeing little reason to press on, the company promptly disbanded, winding down in its operations in about 30 days, Martin said. Cebix had raised nearly $50 million on its way into the failed Phase IIb, drawing the support of InterWest, Sofinnova Ventures and Thomas, McNerney & Partners. And, counting on Ersatta's success, last year the company started putting together a $35 million new round to pay its way toward late-stage studies, according to an SEC filing . Instead, Martin and his team are now out scouting for new startup opportunities, he said. Targeting C peptide to treat diabetes has something of a checkered clinical history. Tolerx , alongside partner GlaxoSmithKline ( $GSK ), developed an antibody designed to boost levels of the hormone but bombed out in Phase III, and the biotech met a fate similar to Cebix's in 2011. And teplizumab, another antibody crafted to preserve C peptide, came up short for Eli Lilly ( $LLY ) in a Phase III study, but its biotech partner, MacroGenics ( $MGNX ), has since revived the program and found some success in early-stage diabetics. - read the Xconomy story

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cebix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cebix is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,734 items

Cebix Patents

Cebix has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/19/2012

2/24/2015

Diabetes, Insulin therapies, Human proteins, Peptide hormones, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/19/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/24/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Diabetes, Insulin therapies, Human proteins, Peptide hormones, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.